Sequenom ( and SensiGen ( inked a collaborative agreement to jointly market SensiGen’s AttoSense™ tests. SensiGen’s proprietary methodology utilizes Sequenom’s QGE gene-expression technology and MassARRAY® system for the detection of major diseases, including cervical cancer, chronic kidney disease, inflammatory bowel disease, and lupus. The two companies will jointly market tests and systems to commercial reference laboratories worldwide. Under the agreement, Sequenom will exclusively supply the platform technology used for commercializing SensiGen’s tests.

Next articleUMMZ Periodical Cicada Page